> Isotechnika's ISA247 has demonstrated significant efficacy against psoriasis. Report
> Romark Laboratories has begun enrolling patients in a U.S. clinical trial to evaluate nitazoxanide for the treatment of chronic hepatitis C. Preliminary data from the study is expected in the second half of 2008. Release
> It was inevitable: All the chit-chat about drug safety and the FDA's shortcomings had to result in legislation. Rep. John Dingell's House Energy and Commerce Committee released a "discussion draft" yesterday, planning to convene hearings over the next few weeks and draw up the real bill after that. Report
> Pfizer shares hit a 10-year low yesterday. And who can blame investors who sold, considering the Eeyore tone Wall Street analysts took after the drugmaker announced its falling sales and earnings? Report
> Call it the backlash against the backlash. In the wake of the recent Vytorin and Vioxx marketing scandals, drugmakers are banding together to prevent a Congressional crackdown on their power to promote. Report
And Finally… Researchers at Purdue say they're on to a new bird flu vaccine that offers broader protection over a longer period of time. Article